Anita D'Souza, MD, discusses an abstract looking at the combination of teclistamab-cqyv, daratumumab, and pomalidomide in 2 ...

Survival in multiple myeloma has improved significantly with the advent of novel, more potent immunotherapies, including CAR ...

A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...

Study of frail older adult patients with myeloma showed reduced disease progression and death with a regimen reducing dexamethasone exposure.

A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...

Tony Newberne is a high-risk myeloma survivor. He is also a CPT, dietary manager, and patient advocate for several nonprofits ...

Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition ...

Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as ...

Bispecific antibodies show strong initial uptake in community settings for multiple myeloma treatment, particularly among ...

The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...

Including 24-hour urine testing in multiple myeloma response assessments is largely unnecessary, a new phase 3 trial suggests ...